Atomwise has revealed significant findings from its AIMS (Artificial Intelligence Molecular Screen) initiative, proving the AtomNet AI Platform as a strong alternative to traditional high-throughput screening for drug discovery. Published in Nature Scientific Reports, the study showed AtomNet identified structurally novel hits for 235 targets, greatly improving hit success rates compared to traditional HTS.
Atomwise’s AIMS Initiative Proves AtomNet AI Platform as a Superior Alternative to Traditional High-Throughput Screening in Drug Discovery – Draper Decentralized – 6.3.24
Published June 3, 2024